Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Voyager Therapeutics (VYGR) Return on Capital Employed: 2015-2025

Historic Return on Capital Employed for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to -0.52%.

  • Voyager Therapeutics' Return on Capital Employed fell 54.00% to -0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.52%, marking a year-over-year decrease of 54.00%. This contributed to the annual value of -0.26% for FY2024, which is 90.00% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Return on Capital Employed stood at -0.52%, which was down 24.57% from -0.42% recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Return on Capital Employed peaked at 0.47% during Q4 2023, and registered a low of -0.65% during Q1 2022.
  • Its 3-year average for Return on Capital Employed is -0.01%, with a median of -0.02% in 2024.
  • As far as peak fluctuations go, Voyager Therapeutics' Return on Capital Employed slumped by 76bps in 2021, and later skyrocketed by 106bps in 2023.
  • Voyager Therapeutics' Return on Capital Employed (Quarterly) stood at -0.53% in 2021, then rose by 2bps to -0.52% in 2022, then spiked by 99bps to 0.47% in 2023, then slumped by 70bps to -0.23% in 2024, then crashed by 54bps to -0.52% in 2025.
  • Its Return on Capital Employed stands at -0.52% for Q3 2025, versus -0.42% for Q2 2025 and -0.31% for Q1 2025.